Effects of cytokine gene therapy on particulate-induced inflammation in the murine air pouch.
Retroviral vectors encoding the human IL-1 antagonist (IL-1Ra) gene and the human tumor necrosis factor soluble receptor (sTNF-R) gene were investigated using an in vivo model of the inflammatory response to orthopedic wear debris. Air pouches established in BALB/c mice were injected with polymethylmethacrylate (PMMA) particles to provoke an inflammatory reaction, and infected with retroviral vectors expressing IL-1Ra, sTNF-R or a LacZ marker gene. Pouch membranes and fluids were harvested after 48 or 72 hours for analyses. Positive PCR reactions for Neo genes were observed specifically in DNA extracted from the membrane of retroviral-infected pouches. ELISA assays revealed the presence of human IL-1 Ra in pouch fluid from DFG-IRAP-Neo transduced mice, but not control animals. Histological evaluation indicated that the IL-1Ra gene transfer was associated with markedly decreased inflammation in the model, with resolution of the edematous phase of the reaction, decreased pouch fluid accumulation, and lowered macrophage influx. The data suggest that the air pouch model represents a useful tool to evaluate gene therapy, and demonstrate that IL-1Ra gene therapy may be an appropriate therapeutic approach to inflammation.
Sud
S
S
Department of Orthopaedic Surgery, Wayne State University School of Medicine, Detroit, Ml 48201, USA.
Yang
S Y
SY
Evans
C H
CH
Robbins
P D
PD
Wooley
P H
PH
D000818:Animals; D001672:Biocompatible Materials / Q000009:adverse effects*; D016207:Cytokines / Q000235:genetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000627:therapeutic use; D007249:Inflammation / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D019904:Polymethyl Methacrylate / Q000009:adverse effects; D017472:Receptors, Interleukin-1 / Q000235:genetics / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000627:therapeutic use; D012190:Retroviridae / Q000235:genetics; D016896:Treatment Outcome
D001672:Biocompatible Materials; D016207:Cytokines; D017472:Receptors, Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D019904:Polymethyl Methacrylate